Vol. 51 | No. 2 | July-December 2023 Back

Open Access

Eosinophil-to-Leukocyte Ratio as an Inflammatory Marker in Patients With Coronary Artery Disease—A Retrospective Cohort Study

Arlene Melissa T. Dychiching, Henry L. Chan
Dec 2023 DOI 10.69944/pjc.9d2aeda181

Abstract

BACKGROUND: Cardiovascular disease remains one of the leading causes of death and major causes of disability and loss of productivity in adults worldwide. Inflammation is a key feature of atherosclerosis and its clinical manifestations. Because inflammation plays a key role in atherosclerosis and its end results, discovering new biomarkers of inflammation becomes important to help diagnostic accuracy and provide prognostic information about coronary artery disease (CAD). The eosinophil count and eosinophil-to-leukocyte ratio (ELR), in particular, have become novel biomarkers for risk assessment in patients with CAD. The current study aimed to evaluate the association of ELR with presence of CAD.

OBJECTIVES: The aim of this study was to investigate the prognostic value and predictive performance of ELR in patients with suspected CAD. Furthermore, if proven of value, this study aims to use ELR as a biomarker for screening patients at risk for CAD for early prevention and intervention.

METHODS: This is a retrospective cohort study involving a chart review of CAD suspects 40 years or older who underwent elective coronary angiogram from January 2019 to December 2019. Eosinophil-to-leukocyte ratio was calculated by dividing the number of eosinophils by the number of leukocytes

RESULTS: A total of 436 patients were included in this study. With an optimal cutoff value of 0.5 (area under the curve, 0.9911; sensitivity, 96.63%; specificity, 95.27%), ELR demonstrated efficiency in detecting CAD.

CONCLUSION: Patients with CAD has a higher ELR than those without CAD in the control group. Furthermore, this study supports the positive association of ELR in predicting CAD.

 

KEYWORDS: eosinophil-to-leukocyte ratio, coronary artery disease 

References
  1. World Health Organization. Cardiovascular diseases (CVDs). www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). 
  2. Gong S, Gao X, Xu F, et al. Association of lymphocyte to monocyte ratio with severity of coronary artery disease. Medicine (Baltimore) 2018;97(43):e12813. doi: 10.1097/MD.0000000000012813. 
  3. Kamal S, Patel AK, Shah KH, Konat A. Is neutrophil- to-lymphocyte ratio a predictor of coronary artery disease in Western Indians? Int J Inflam 2017:2017:1-8. doi:10.1155/2017/4136126. 
  4. Bergmann K, Sypniewska G. Is there an association of  allergy and cardiovascular disease? Biochem Med (Zagreb) 2011;21(3):210-218. doi: 10.11613/bm.2011.030. 
  5. Jafarzadeh A, Esmaeili Nadimi A, Tajeek H. Serum IgE  levels in patients with ischemic heart disease. Iran Heart J 2004;5:20-25. 
  6. Nadimi AE, Ahmadi J, Mehrabian M. Peripheral eosinophil  count and allergy in patients with coronary artery disease. Acta Med Indones 2008;40(2):74-77. 
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.